TransMedics Group (TMDX) Tops Q2 EPS by 10c ; Offers Guidance

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of ($0.03), $0.10 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $52.5 million versus the consensus estimate of $42.43 million.

GUIDANCE:

TransMedics Group sees Q3 2023 revenue of $180-190 million, versus the consensus of $174 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance